GeneDx Holdings Corp. (WGS)
NASDAQ • Healthcare
Last close at September 16, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, GeneDx Holdings Corp. currently loses $16.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Oct 27
in 41 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
GeneDx’s second fiscal quarter of 2026 featured revenue that topped consensus, as results reported August 3, 2026 showed revenue of $114.4 million against a $111.0 million estimate (+3.1%), rising 11.4% year over year from $102.7 million. Gross profit came in at roughly $78.2 million, translating to a gross margin of about 68%, while operating results remained negative with operating income of -$17.5 million and an operating margin of around -15%. The quarter ended with net income of -$17.7 million, down from $10.8 million a year ago, and cash generation was also negative, with operating cash flow of -$29.0 million. For the next period, consensus calls for EPS of $0.07 on revenue of $123.0 million.
About GeneDx Holdings Corp.
GeneDx Holdings Corp. provides genomic testing and data-driven research tools in healthcare and trades on the NASDAQ under WGS. The company uses large clinical and genomic datasets to support diagnostic and research work, and it generated $427.5 million of revenue in FY2025.
Today's Snapshot
WGS closed 2.9% higher on heavier trading than usual.
Trading Volume
Above 10d avg 538.9K
785.9K
vs S&P 500 Today
Strong Outperformance
+3.52%
Updated: September 16, 2026 at 20:13 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$75.38 - $89.51Buy
- RSI (14)72.79Sell
- Stochastic %K (14, 3, 3)83.00Sell
- MACD Level (12, 26)4.38Buy
Peers & Related Assets
Get premium market insights delivered directly to your inbox.